1. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Issue 2 (25th February 2022) Authors: Schöffski, Patrick; Tan, Daniel S W; Martín, Miguel; Ochoa-de-Olza, María; Sarantopoulos, John; Carvajal, Richard D; Kyi, Chrisann; Esaki, Taito; Prawira, Amy; Akerley, Wallace; De Braud, Filippo; Hui, Rina; Zhang, Tian; Soo, Ross A; Maur, Michela; Weickhardt, Andrew; Krauss, Jürgen; Deschler-Bai... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 2(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗